Psivant Therapeutics
Christina Bracken is a highly experienced biologist currently serving as Principal Scientist and Biology Lead at Psivant Therapeutics since July 2024. With a background in preclinical biology, Christina has held various leadership roles, including Associate Director of Preclinical Biology at Redona Therapeutics from November 2019 to July 2024 and Associate Director of Pre-Clinical Pharmacology at PreciThera, Inc. from September 2018 to June 2019. Prior to these positions, Christina contributed to translational biology at Mitobridge, Inc. and specialized in tissue protection and repair at Sanofi Genzyme. Christina's earlier research experience includes work at Tufts University and the Marine Biological Laboratory, where significant projects involved BMP signaling in development and drug resistance in Schistosoma species. Christina holds a Master of Science in Biology from Tufts University and a Bachelor of Science in Biology from Simmons University.
Psivant Therapeutics
Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design that is tightly coupled to chemistry and biology research and development. Our QUAISAR platform is purpose-built to develop novel small molecule therapeutics to address biologically and genetically validated, but previously intractable, protein targets.